Core Viewpoint - Arcutis Biotherapeutics, Inc. (ARQT) has seen a 2.3% increase in share price over the past four weeks, closing at $13.40, with a potential upside of 48.4% based on Wall Street analysts' mean price target of $19.88 [1] Price Targets - The average price target consists of eight estimates ranging from a low of $15 to a high of $29, with a standard deviation of $4.22, indicating variability among analysts [2] - The lowest estimate suggests an 11.9% increase from the current price, while the highest estimate indicates a potential upside of 116.4% [2] - A low standard deviation signifies greater agreement among analysts regarding price movement [2][7] Analyst Sentiment - Analysts are optimistic about ARQT's earnings prospects, as indicated by a positive trend in earnings estimate revisions, which historically correlate with stock price movements [4][9] - Over the last 30 days, the Zacks Consensus Estimate for the current year has increased by 34.4%, with three estimates moving higher and no negative revisions [10] Zacks Rank - ARQT holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, suggesting strong potential for upside [11] Caution on Price Targets - While price targets are a common metric, relying solely on them for investment decisions may not be prudent due to historical inaccuracies in predicting actual stock price movements [3][5][8]

Core Viewpoint - AutoZone, Inc. is expected to report an increase in quarterly earnings and revenue in its upcoming financial results, indicating positive growth trends for the company [1]. Financial Performance - AutoZone is projected to report quarterly earnings of $28.98 per share, an increase from $28.89 per share in the same period last year [1]. - The company anticipates quarterly revenue of $3.98 billion, compared to $3.86 billion a year earlier [1]. - In the fiscal first quarter, AutoZone reported earnings per share of $32.52, which was below the expected $33.76 [2]. Stock Performance and Analyst Ratings - AutoZone shares closed at $3,493.01, reflecting a gain of 1.4% [2]. - Barclays analyst Matthew McClintock raised the price target for AutoZone from $3,024 to $3,585, maintaining an Overweight rating [3]. - Argus Research analyst Bill Selesky increased the price target from $3,560 to $3,678 while maintaining a Buy rating [3]. - TD Cowen analyst Max Rakhlenko raised the price target from $3,450 to $3,800, also maintaining a Buy rating [3]. - BMO Capital analyst Tristan Thomas-Martin initiated coverage with an Outperform rating and a price target of $3,700 [3]. - Wells Fargo analyst Zachary Fadem increased the price target from $3,450 to $3,750 while maintaining an Overweight rating [3].